Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed a Form 8-K on July 25, 2025, reporting events that occurred on July 24, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document addresses regulatory compliance status rather than financial performance.
Material Changes
The primary material event is the confirmation by the Nasdaq Office of General Counsel that the Company has demonstrated compliance with the Stockholders' Equity requirement under Nasdaq Listing Rule 5550(b)(1). Consequently, the Company is currently in compliance with Nasdaq Capital Market continued listing requirements.
Outlook, Risks, and Contingencies
- Mandatory Panel Monitor: The Company is subject to a Mandatory Panel Monitor for a period of one year from July 24, 2025.
- Delisting Risk: If the Nasdaq Listing Qualifications Staff determines the Company is out of compliance with the Stockholders' Equity Rule within the one-year monitoring period, a delisting determination letter will be issued.
- Restricted Remedies: During the monitoring period, the Company will not be permitted to provide a plan of compliance, will not be granted additional time to regain compliance, and will not be afforded a cure period under Nasdaq Listing Rule 5810(c)(3).
- Appeal Rights: In the event of a delisting determination, the Company will have an opportunity to request a new hearing with Nasdaq's Hearings Panel.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to ensure it remains above the Nasdaq threshold.
- Monitor future 8-K filings for any notices of non-compliance or delisting determination letters from Nasdaq.
- Review the Company's most recent 10-Q or 10-K for detailed financial position and cash runway, as this 8-K does not provide such data.